ESMO Immuno-Oncology 2025 | What are the advantages of co-targeting of LAG-3 and PD-1 in oncology?
Jesus Fuentes-Antras, MD, NEXT Oncology Madrid, Hospital Universitario Quirónsalud Madrid, Madrid, Spain, comments on the benefits of a bispecific antibody targeting LAG-3 and PD-1 over individual targeting. There is potential for more efficient modulation of the immune synapse, more predictable pharmacokinetics and pharmacodynamics, and easier dosing, which could lead to higher efficacy with less toxicity. These targets are well-known and validated, particularly in melanoma, and that co-targeting them at the single cell level could have several benefits. This interview took place at 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress in London, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think that’s one of the key questions. So I want to elaborate again on LAG3-VMP1 by themselves. I think these are very well-known targets and actually validated, for instance, in melanoma. So the goal here was to explore, to show that a Bispecific may have several benefits. And what those benefits are essentially is first from a biological rationalist to have a more efficient modulation of the immune synapse by co-targeting at the single cell level...
I think that’s one of the key questions. So I want to elaborate again on LAG3-VMP1 by themselves. I think these are very well-known targets and actually validated, for instance, in melanoma. So the goal here was to explore, to show that a Bispecific may have several benefits. And what those benefits are essentially is first from a biological rationalist to have a more efficient modulation of the immune synapse by co-targeting at the single cell level. Second, I would say from a PK-PD perspective, this is not a combination of two different agents, but just one. So we may understand that PKs are going to be more predictable and pharmacodynamics as well. And a third, this is going to be directly related to the fact that dosing is going to be easier. So in terms of development and achieving higher doses, the development should be easier. Finally, this as well would lead to higher doses, more efficacy, but having less toxicity at the same time because we’d be more efficient in this co-targeting. I think these three key aspects are the points to highlight why we need to develop these specific compounds.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
